| A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging L Keren, M Bosse, D Marquez, R Angoshtari, S Jain, S Varma, SR Yang, ... Cell 174 (6), 1373-1387. e19, 2018 | 799 | 2018 |
| Precision medicine in non-small cell lung cancer: Current applications and future directions SR Yang, AM Schultheis, H Yu, D Mandelker, M Ladanyi, R Büttner Seminars in cancer biology 84, 184-198, 2022 | 162 | 2022 |
| Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer RS Vanguri, J Luo, AT Aukerman, JV Egger, CJ Fong, N Horvat, ... Nature cancer 3 (10), 1151-1164, 2022 | 96 | 2022 |
| ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer A Passaro, N Leighl, F Blackhall, S Popat, K Kerr, MJ Ahn, ME Arcila, ... Annals of Oncology 33 (5), 466-487, 2022 | 86 | 2022 |
| Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS A Rose Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, ... Nature Communications 12 (1), 3770, 2021 | 84 | 2021 |
| A performance comparison of commonly used assays to detect RET fusions SR Yang, U Aypar, EY Rosen, DA Mata, R Benayed, K Mullaney, ... Clinical Cancer Research 27 (5), 1316-1328, 2021 | 57 | 2021 |
| Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry A Drilon, M Duruisseaux, JY Han, M Ito, C Falcon, SR Yang, ... Journal of Clinical Oncology 39 (25), 2791, 2021 | 41 | 2021 |
| Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma SR Yang, CY Lin, H Stehr, SR Long, CS Kong, GJ Berry, JL Zehnder, ... The Journal of Molecular Diagnostics 20 (2), 184-194, 2018 | 36 | 2018 |
| Molecular characterization of peritoneal mesotheliomas M Offin, SR Yang, J Egger, G Jayakumaran, RS Spencer, J Lopardo, ... Journal of Thoracic Oncology 17 (3), 455-460, 2022 | 35 | 2022 |
| Rare molecular subtypes of lung cancer G Harada, SR Yang, E Cocco, A Drilon Nature Reviews Clinical Oncology 20 (4), 229-249, 2023 | 33 | 2023 |
| Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers NJ Choudhury, A Marra, JSY Sui, J Flynn, SR Yang, CJ Falcon, ... Journal of Thoracic Oncology 18 (4), 463-475, 2023 | 33 | 2023 |
| Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions DA Mata, JK Benhamida, AL Lin, CM Vanderbilt, SR Yang, LB Villafania, ... Acta neuropathologica communications 8, 1-13, 2020 | 33 | 2020 |
| Ultrarapid EGFR mutation screening followed by comprehensive next-generation sequencing: a feasible, informative approach for lung carcinoma cytology specimens with a high … ME Arcila, SR Yang, A Momeni, DA Mata, P Salazar, R Chan, D Elezovic, ... JTO clinical and research reports 1 (3), 100077, 2020 | 32 | 2020 |
| Invasive mucinous adenocarcinomas with spatially separate lung lesions: analysis of clonal relationship by comparative molecular profiling SR Yang, JC Chang, C Leduc, KS Tan, S Dogan, R Benayed, L Borsu, ... Journal of Thoracic Oncology 16 (7), 1188-1199, 2021 | 27 | 2021 |
| Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers NJ Choudhury, JL Schneider, T Patil, VW Zhu, DA Goldman, SR Yang, ... JTO Clinical and Research Reports 2 (7), 100187, 2021 | 22 | 2021 |
| Clinical experience of cerebrospinal fluid–based liquid biopsy demonstrates superiority of cell-free DNA over cell pellet genomic DNA for molecular profiling TA Bale, SR Yang, JP Solomon, K Nafa, S Middha, J Casanova, ... The Journal of Molecular Diagnostics 23 (6), 742-752, 2021 | 21 | 2021 |
| Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions CY Lin, K Mooney, W Choy, SR Yang, K Barry-Holson, K Horst, I Wapnir, ... Modern Pathology 31 (4), 562-568, 2018 | 20 | 2018 |
| Targeted deep sequencing of cell‐free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology SR Yang, KL Mooney, P Libiran, CD Jones, R Joshi, HD Lau, H Stehr, ... Cancer Cytopathology 128 (1), 43-56, 2020 | 19 | 2020 |
| Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy C Kyi, CF Friedman, JJ Mueller, R Benayed, M Ladanyi, M Arcila, ... Gynecologic Oncology Reports 37, 100852, 2021 | 17 | 2021 |
| Clinical utility and performance of an ultrarapid multiplex RNA-based assay for detection of ALK, ROS1, RET, and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations YH Chu, J Barbee, SR Yang, JC Chang, P Liang, K Mullaney, R Chan, ... The Journal of Molecular Diagnostics 24 (6), 642-654, 2022 | 16 | 2022 |
